Skip to main content
. Author manuscript; available in PMC: 2025 Apr 18.
Published in final edited form as: Cell Chem Biol. 2023 Dec 6;31(4):805–819.e9. doi: 10.1016/j.chembiol.2023.11.007

Figure 4: Structural analogs reveal a potent MYCN inhibitor and preliminary SAR data.

Figure 4:

(A) Chemical structure of isopomiferin and five analogs, ranked by potency in cell viability assays.

(B) Dose-response curves of SK-N-Be2 cells treated with isopomiferin analogs for 72 h. Data represent the mean from three replicate experiments, and error bars represent standard deviation across experiments (mean ± S.D.).

(C) MYCN abundance in SK-N-Be2 cells treated with isopomiferin, pomiferin, pomiferin dimethyl ether, or hydrogenated pomiferin for 24 h.

(D) Western blot analysis of MYCN and TEAD4 abundance in SK-N-Be2 cells following treatment with pomiferin for 24 h.

(E) Western blot analysis of MYCN abundance in SK-N-Be2 cells following treatment with 10 µM pomiferin across time.

(F) Transcript abundance of three direct targets of MYCN associated with poor patient outcome. SK-N-Be2 cells treated with 10 µM pomiferin for indicated time point. Values represent mean ± S.D. of three biological replicates.